Company intelligence / Profile preview
Chengdu Weisk Biopharmaceutical
Chengdu, Sichuan, Chinawestvacpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has developed multiple vaccines and immunotherapies, including a recombinant protein COVID-19 vaccine approved in China. Its mRNA-based cancer vaccines have shown superior safety and efficacy compared to other mRNA cancer vaccines in investigator-led trials for nasopharyngeal carcinoma and NK/T-cell lymphoma. The lead candidate WGc-043 is the first mRNA therapeutic cancer vaccine approved to start US trials for EB virus-related cancers[1][5]. The company also has IND approval for its EB virus-associated neoplasm program.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- mRNA vaccineProphylactic vaccineTherapeutic vaccineGenetically engineered subunit vaccine
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Chengdu Weisk Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Weisk Biopharmaceutical.